Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,418,197

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $471.75 -0.10 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Varian's ProBeam Compact System Picked by University of Miami

by Zacks Equity Research

Varian (VAR) sees notable developments in its Proton Solutions business of late.

Zacks Equity Research

DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

DexCom (DXCM) has various favorable factors to maintain the current high.

Zacks Equity Research

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.

Zacks Equity Research

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

Zacks Equity Research

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.

Zacks Equity Research

Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform

by Zacks Equity Research

Veeva's (VEEV) Vault platform sees a slew of developments in recent times.

Zacks Equity Research

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

by Zacks Equity Research

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio

by Zacks Equity Research

Stryker (SYK) gains from core segments in the second quarter of 2019.

Zacks Equity Research

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

Zacks Equity Research

Here's Why You Should Snap Up Baxter International (BAX) Now

by Zacks Equity Research

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

Zacks Equity Research

Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.

Zacks Equity Research

Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

by Zacks Equity Research

Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.

Zacks Equity Research

Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y

by Zacks Equity Research

Nevro (NVRO) sees dismal segmental performance in Q2.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered

by Zacks Equity Research

Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.

Zacks Equity Research

Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

by Zacks Equity Research

Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.

Zacks Equity Research

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Benjamin Rains headshot

Adidas Slips, Lyft Climbs, Uber Earnings & Why Intuitive Surgical Stock is a Strong Buy | Free Lunch

by Benjamin Rains

On today's episode of Free Lunch here at Zacks, Associate Stock Strategist Ben Rains offers a quick global economic update. The episode also dives into Adidas (ADDYY), Lyft (LYFT), and Uber (UBER) earnings, and more...

Zacks Equity Research

Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.

Zacks Equity Research

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

LHC Group (LHCG) second-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.

Zacks Equity Research

Wright Medical (WMGI) Earnings Beat in Q2, Guidance Slashed

by Zacks Equity Research

Wright Medical (WMGI) gains from Upper and Lower Extremities units in Q2; slashes 2019 view.

Zacks Equity Research

Cardiovascular Systems (CSII) Earnings Match Estimates in Q4

by Zacks Equity Research

We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Zacks Equity Research

CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance

by Zacks Equity Research

CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.

Zacks Equity Research

Avanos (AVNS) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Avanos (AVNS) second-quarter results benefit from higher revenues, strong segmental performance and expansion in margins.